Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445809 · ClinicalTrials.gov registry record
Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury
A clinical trial, sponsored by Abbott RDx Cardiometabolic.
- Completed
- Registry status
- 355
- Enrollment target
NCT00445809 is a clinical trial that has completed, run by Abbott RDx Cardiometabolic. The registered enrollment target is 355 participants.
The verdict
NCT00445809 has completed, sponsored by Abbott RDx Cardiometabolic.
- COMPLETED
- Registry status
- 355 participants
- Enrollment target
Study Summary
Some patients who undergo cardiovascular surgery requiring cardiopulmonary bypass will develop a kidney injury following their surgery. The purpose of this study is to take a blood sample from patients before they have this type of surgery and then at nine time points after their surgery to test their plasma for a biomarker called NGAL and compare the NGAL levels to their creatinine levels. We hypothesize that NGAL is an earlier marker for kidney injury than creatinine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445809
The ClinicalTrials.gov registry entry for NCT00445809 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott RDx Cardiometabolic, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00445809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00445809 about?
NCT00445809 is a clinical study titled "Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury". Some patients who undergo cardiovascular surgery requiring cardiopulmonary bypass will develop a kidney injury following their surgery. The purpose of this study is to take a blood sample from patients before they have this type of surgery and then at nine time points after their surgery to test the...
What is the current status of trial NCT00445809?
This trial is currently completed. The enrollment target is 355 participants. The study started on 2007-02. Estimated completion is 2009-04.
Who is sponsoring clinical trial NCT00445809?
This trial is sponsored by Abbott RDx Cardiometabolic, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.